Precigen (NASDAQ:PGEN) Given New $10.00 Price Target at HC Wainwright

Precigen (NASDAQ:PGEN) had its target price increased by HC Wainwright from $9.00 to $10.00 in a report published on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on the stock. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Precigen Trading Up 25.3%

NASDAQ PGEN opened at $3.89 on Thursday. Precigen has a 12 month low of $1.11 and a 12 month high of $5.47. The company has a 50-day moving average of $4.10 and a 200-day moving average of $3.98. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95. The company has a market cap of $1.37 billion, a P/E ratio of -2.90 and a beta of 1.10.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.09. Precigen had a negative net margin of 2,588.21% and a negative return on equity of 2,313.82%. The business had revenue of $4.57 million for the quarter, compared to analyst estimates of $8.29 million. As a group, equities analysts predict that Precigen will post -0.32 earnings per share for the current year.

Institutional Trading of Precigen

Institutional investors and hedge funds have recently bought and sold shares of the business. Investment Insight Wealth Management LLC purchased a new position in Precigen in the fourth quarter valued at approximately $443,000. Invesco Ltd. grew its stake in Precigen by 250.8% during the fourth quarter. Invesco Ltd. now owns 373,782 shares of the biotechnology company’s stock worth $1,562,000 after buying an additional 267,223 shares during the period. NewEdge Advisors LLC purchased a new stake in Precigen during the fourth quarter worth approximately $45,000. XTX Topco Ltd increased its position in shares of Precigen by 25.2% in the fourth quarter. XTX Topco Ltd now owns 49,668 shares of the biotechnology company’s stock worth $208,000 after acquiring an additional 10,005 shares in the last quarter. Finally, VARCOV Co. acquired a new stake in shares of Precigen in the fourth quarter worth $224,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: PAPZIMEOS commercial momentum — Precigen reports accelerating U.S. launch demand, broad payer coverage and expects Q1 revenue to exceed $18M (company guidance), supporting a rising near‑term revenue run‑rate. Precigen expects Q1 revenue to exceed $18M
• Positive Sentiment: CMS coding and access tailwind — A permanent J‑code (J3404) for PAPZIMEOS effective April 1 will streamline claims and likely improve reimbursement/uptake. This is a direct commercial enabler for sustained sales growth. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms raised targets/ratings (Citizens JMP to $9, HC Wainwright to $10), signaling stronger sell‑side conviction around commercial upside and valuation re‑rating. Benzinga price target coverage
• Positive Sentiment: Cash runway and breakeven plan — Management reports ~$100.4M in cash and expects operations to reach cash‑flow breakeven in 2026, reducing near‑term financing risk. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Neutral Sentiment: Analyst valuation note — A recent Seeking Alpha piece models scenario‑weighted fair value around $6.13 (base case ~$7.01), highlighting upside versus current levels but dependent on sustained commercial execution. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Regulatory/clinical updates — EMA validated an MAA for PAPZIMEOS and an open‑label redosing study was initiated; these are medium‑term positives but will take time to materially affect revenue. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Negative Sentiment: Mixed Q4 results — EPS slightly beat expectations (reported roughly breakeven per share vs. a larger expected loss), but product/total revenue of ~$4.57M missed consensus (~$8.3M), showing launch sales still ramping and generating near‑term volatility in reported numbers. PGEN Q4 earnings summary
• Negative Sentiment: Short‑term execution risk — Revenue is still concentrated on an early launch with payer rollout timing and demand variability; missed revenue estimates underscore execution risk that could pressure the stock if quarterly cadence disappoints. Zacks: Precigen Reports Q4 Loss, Lags Revenue Estimates

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.